@article{Rodrigo Santacruz_Neus Villamor_Marta Aymerich_Alejandra Martínez-Trillos_Cristina López_Alba Navarro_María Rozman_Sílvia Beà_Cristina Royo_Maite Cazorla_Dolors Colomer_Eva Giné_Magda Pinyol_Xose S. Puente_Carlos López-Otín_Elías Campo_Armando López-Guillermo_Julio Delgado_2014, place={Pavia, Italy}, title={The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy}, volume={99}, url={https://haematologica.org/article/view/7032}, DOI={10.3324/haematol.2013.099796}, abstractNote={A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of <em>IGHV</em>, <em>TP53</em>, <em>NOTCH1</em> and <em>SF3B1</em> mutations. The median follow-up was 73 months (range, 2–202) from disease evaluation. The median treatment-free survival durations for patients achieving a complete response without or with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively (<em>P</em><0.001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (<em>P</em><0.001), <em>IGHV</em> status (<em>P</em><0.001) and β<sub>2</sub>-microglobulin levels (<em>P</em>=0.012). With regards to overall survival, factors predictive of an unfavorable outcome were minimal residual disease positivity (<em>P</em>=0.014), together with advanced age (<em>P</em><0.001), unmutated <em>IGHV</em> status (<em>P</em>=0.001), <em>TP53</em> mutations (<em>P</em><0.001) and elevated levels of β<sub>2</sub>-microglobulin (<em>P</em&gt;=0.003). In conclusion, for patients requiring front-line therapy, achievement of minimal residual disease negativity is associated with significantly prolonged treatment-free and overall survival irrespective of other prognostic markers or treatment administered.}, number={5}, journal={Haematologica}, author={Rodrigo Santacruz and Neus Villamor and Marta Aymerich and Alejandra Martínez-Trillos and Cristina López and Alba Navarro and María Rozman and Sílvia Beà and Cristina Royo and Maite Cazorla and Dolors Colomer and Eva Giné and Magda Pinyol and Xose S. Puente and Carlos López-Otín and Elías Campo and Armando López-Guillermo and Julio Delgado}, year={2014}, month={Apr.}, pages={873-880} }